Article

Rennee Rayburg, RPh, Discusses the Top Down Approach in Specialty Drug Management

Renee Rayburg, RPh, Manager Clinical Pharmacy, OptumInsight, states that if providers narrowly focus on the traditional top down approach in specialty drug management they may miss out on opportunities for additional cost savings.

Renee Rayburg, RPh, Manager Clinical Pharmacy, OptumInsight, states that if providers narrowly focus on the traditional top down approach in specialty drug management they may miss out on opportunities for additional cost savings.

When providers only focus on their top drivers, they fail to recognize the impact specialty drug patients can have on pushing higher costs. Rayburg says, “When you look at a rare disease and a drug that might cost you a couple hundred thousand dollars a year, it’s going to make a difference if you have one or two of those in your population of people.”

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Surbhi Sidana, MD, MBBS, Stanford University
Gordon Crofoot, MD, PA
David Awad, PharmD, BCOP
Merrill H. Stewart, MD
Saad Z. Usmani, MD, MBA, FACP, FASCO, Memorial Sloan Kettering Cancer Center
Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center
Hamlet Gasoyan, PhD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo